Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
Identifieur interne : 002764 ( PubMed/Checkpoint ); précédent : 002763; suivant : 002765Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
Auteurs : B G Feagan [Canada] ; W J Sandborn [États-Unis] ; G. D'Haens [Pays-Bas] ; S D Lee [États-Unis] ; M. Allez [France] ; R N Fedorak [Canada] ; U. Seidler [Allemagne] ; S. Vermeire [Belgique] ; I C Lawrance [Australie] ; A C Maroney [États-Unis] ; C H Jurgensen [États-Unis] ; A. Heath [États-Unis] ; D J Chang [États-Unis]Source :
- Alimentary pharmacology & therapeutics [ 1365-2036 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Complexe antigénique L1 leucocytaire (métabolisme), Femelle, Fèces, Humains, Jeune adulte, Maladie de Crohn (traitement médicamenteux), Mâle, Méthode en double aveugle, Protéine C-réactive (métabolisme), Récepteurs CCR (antagonistes et inhibiteurs), Sulfonamides (usage thérapeutique).
- MESH :
- antagonistes et inhibiteurs : Récepteurs CCR.
- métabolisme : Complexe antigénique L1 leucocytaire, Protéine C-réactive.
- traitement médicamenteux : Maladie de Crohn.
- usage thérapeutique : Sulfonamides.
- Adulte, Adulte d'âge moyen, Femelle, Fèces, Humains, Jeune adulte, Mâle, Méthode en double aveugle.
English descriptors
- KwdEn :
- MESH :
- chemical , antagonists & inhibitors : Receptors, CCR.
- chemical , metabolism : C-Reactive Protein, Leukocyte L1 Antigen Complex.
- drug therapy : Crohn Disease.
- chemical , therapeutic use : Sulfonamides.
- Adult, Double-Blind Method, Feces, Female, Humans, Male, Middle Aged, Young Adult.
Abstract
Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatments.
DOI: 10.1111/apt.13398
PubMed: 26400458
Affiliations:
- Allemagne, Australie, Belgique, Canada, France, Pays-Bas, États-Unis
- Basse-Saxe, Californie, Hollande-Septentrionale, Pennsylvanie, Washington (État), Île-de-France
- Amsterdam, Hanovre, Paris, Seattle
- Université de Washington
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:26400458Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.</title><author><name sortKey="Feagan, B G" sort="Feagan, B G" uniqKey="Feagan B" first="B G" last="Feagan">B G Feagan</name><affiliation wicri:level="1"><nlm:affiliation>Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Sandborn, W J" sort="Sandborn, W J" uniqKey="Sandborn W" first="W J" last="Sandborn">W J Sandborn</name><affiliation wicri:level="2"><nlm:affiliation>Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="D Haens, G" sort="D Haens, G" uniqKey="D Haens G" first="G" last="D'Haens">G. D'Haens</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Gastroenterology, Academic Medical Centre, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Lee, S D" sort="Lee, S D" uniqKey="Lee S" first="S D" last="Lee">S D Lee</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Allez, M" sort="Allez, M" uniqKey="Allez M" first="M" last="Allez">M. Allez</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Hopital Saint-Louis, APHP, Université Paris Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Gastroenterology, Hopital Saint-Louis, APHP, Université Paris Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Fedorak, R N" sort="Fedorak, R N" uniqKey="Fedorak R" first="R N" last="Fedorak">R N Fedorak</name><affiliation wicri:level="1"><nlm:affiliation>Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Gastroenterology, University of Alberta, Edmonton, AB</wicri:regionArea><wicri:noRegion>AB</wicri:noRegion></affiliation></author><author><name sortKey="Seidler, U" sort="Seidler, U" uniqKey="Seidler U" first="U" last="Seidler">U. Seidler</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Hannover Medical School, Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gastroenterology, Hannover Medical School, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Vermeire, S" sort="Vermeire, S" uniqKey="Vermeire S" first="S" last="Vermeire">S. Vermeire</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Gastroenterology, University Hospitals Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Lawrance, I C" sort="Lawrance, I C" uniqKey="Lawrance I" first="I C" last="Lawrance">I C Lawrance</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute for Medical Research, Fiona Stanley Hospital, Murdoch, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute for Medical Research, Fiona Stanley Hospital, Murdoch, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Maroney, A C" sort="Maroney, A C" uniqKey="Maroney A" first="A C" last="Maroney">A C Maroney</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Jurgensen, C H" sort="Jurgensen, C H" uniqKey="Jurgensen C" first="C H" last="Jurgensen">C H Jurgensen</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Heath, A" sort="Heath, A" uniqKey="Heath A" first="A" last="Heath">A. Heath</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Chang, D J" sort="Chang, D J" uniqKey="Chang D" first="D J" last="Chang">D J Chang</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26400458</idno><idno type="pmid">26400458</idno><idno type="doi">10.1111/apt.13398</idno><idno type="wicri:Area/PubMed/Corpus">002727</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002727</idno><idno type="wicri:Area/PubMed/Curation">002658</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002658</idno><idno type="wicri:Area/PubMed/Checkpoint">002658</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002658</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.</title><author><name sortKey="Feagan, B G" sort="Feagan, B G" uniqKey="Feagan B" first="B G" last="Feagan">B G Feagan</name><affiliation wicri:level="1"><nlm:affiliation>Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON</wicri:regionArea><wicri:noRegion>ON</wicri:noRegion></affiliation></author><author><name sortKey="Sandborn, W J" sort="Sandborn, W J" uniqKey="Sandborn W" first="W J" last="Sandborn">W J Sandborn</name><affiliation wicri:level="2"><nlm:affiliation>Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="D Haens, G" sort="D Haens, G" uniqKey="D Haens G" first="G" last="D'Haens">G. D'Haens</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Gastroenterology, Academic Medical Centre, Amsterdam</wicri:regionArea><placeName><settlement type="city">Amsterdam</settlement><region nuts="2" type="province">Hollande-Septentrionale</region></placeName></affiliation></author><author><name sortKey="Lee, S D" sort="Lee, S D" uniqKey="Lee S" first="S D" last="Lee">S D Lee</name><affiliation wicri:level="4"><nlm:affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, University of Washington, Seattle, WA</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Allez, M" sort="Allez, M" uniqKey="Allez M" first="M" last="Allez">M. Allez</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Hopital Saint-Louis, APHP, Université Paris Diderot, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Department of Gastroenterology, Hopital Saint-Louis, APHP, Université Paris Diderot, Paris</wicri:regionArea><placeName><region type="region">Île-de-France</region><region type="old region">Île-de-France</region><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Fedorak, R N" sort="Fedorak, R N" uniqKey="Fedorak R" first="R N" last="Fedorak">R N Fedorak</name><affiliation wicri:level="1"><nlm:affiliation>Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Division of Gastroenterology, University of Alberta, Edmonton, AB</wicri:regionArea><wicri:noRegion>AB</wicri:noRegion></affiliation></author><author><name sortKey="Seidler, U" sort="Seidler, U" uniqKey="Seidler U" first="U" last="Seidler">U. Seidler</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gastroenterology, Hannover Medical School, Hannover, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gastroenterology, Hannover Medical School, Hannover</wicri:regionArea><placeName><region type="land" nuts="2">Basse-Saxe</region><settlement type="city">Hanovre</settlement></placeName></affiliation></author><author><name sortKey="Vermeire, S" sort="Vermeire, S" uniqKey="Vermeire S" first="S" last="Vermeire">S. Vermeire</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Department of Gastroenterology, University Hospitals Leuven, Leuven</wicri:regionArea><wicri:noRegion>Leuven</wicri:noRegion></affiliation></author><author><name sortKey="Lawrance, I C" sort="Lawrance, I C" uniqKey="Lawrance I" first="I C" last="Lawrance">I C Lawrance</name><affiliation wicri:level="1"><nlm:affiliation>School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute for Medical Research, Fiona Stanley Hospital, Murdoch, WA, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute for Medical Research, Fiona Stanley Hospital, Murdoch, WA</wicri:regionArea><wicri:noRegion>WA</wicri:noRegion></affiliation></author><author><name sortKey="Maroney, A C" sort="Maroney, A C" uniqKey="Maroney A" first="A C" last="Maroney">A C Maroney</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Jurgensen, C H" sort="Jurgensen, C H" uniqKey="Jurgensen C" first="C H" last="Jurgensen">C H Jurgensen</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Heath, A" sort="Heath, A" uniqKey="Heath A" first="A" last="Heath">A. Heath</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author><author><name sortKey="Chang, D J" sort="Chang, D J" uniqKey="Chang D" first="D J" last="Chang">D J Chang</name><affiliation wicri:level="2"><nlm:affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA</wicri:regionArea><placeName><region type="state">Pennsylvanie</region></placeName></affiliation></author></analytic><series><title level="j">Alimentary pharmacology & therapeutics</title><idno type="eISSN">1365-2036</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>C-Reactive Protein (metabolism)</term><term>Crohn Disease (drug therapy)</term><term>Double-Blind Method</term><term>Feces</term><term>Female</term><term>Humans</term><term>Leukocyte L1 Antigen Complex (metabolism)</term><term>Male</term><term>Middle Aged</term><term>Receptors, CCR (antagonists & inhibitors)</term><term>Sulfonamides (therapeutic use)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Complexe antigénique L1 leucocytaire (métabolisme)</term><term>Femelle</term><term>Fèces</term><term>Humains</term><term>Jeune adulte</term><term>Maladie de Crohn (traitement médicamenteux)</term><term>Mâle</term><term>Méthode en double aveugle</term><term>Protéine C-réactive (métabolisme)</term><term>Récepteurs CCR (antagonistes et inhibiteurs)</term><term>Sulfonamides (usage thérapeutique)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Receptors, CCR</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>C-Reactive Protein</term><term>Leukocyte L1 Antigen Complex</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Récepteurs CCR</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Crohn Disease</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Complexe antigénique L1 leucocytaire</term><term>Protéine C-réactive</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Sulfonamides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladie de Crohn</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Sulfonamides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Double-Blind Method</term><term>Feces</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Fèces</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Méthode en double aveugle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatments.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26400458</PMID><DateCreated><Year>2015</Year><Month>10</Month><Day>09</Day></DateCreated><DateCompleted><Year>2016</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2015</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2036</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>10</Issue><PubDate><Year>2015</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Alimentary pharmacology & therapeutics</Title><ISOAbbreviation>Aliment. Pharmacol. Ther.</ISOAbbreviation></Journal><ArticleTitle>Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.</ArticleTitle><Pagination><MedlinePgn>1170-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/apt.13398</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Many patients with active Crohn's disease do not adequately respond to therapies, highlighting the need for new treatments.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To conduct a randomised, double-blind, placebo-controlled phase 3 study to assess the efficacy and safety of vercirnon, an oral inhibitor of CC chemokine receptor-9, for the treatment of patients with moderately-to-severely active Crohn's disease.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with a Crohn's Disease Activity Index (CDAI) of 220-450, plus evidence of active disease (endoscopically confirmed or elevation of both C-reactive protein and faecal calprotectin), who had failed corticosteroid or immunosuppressant therapy were enrolled. Patients were equally randomised to receive placebo, vercirnon 500 mg once daily or vercirnon 500 mg twice daily. The primary endpoint was clinical response, defined as a 100-point decrease in CDAI from baseline to week 12.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Six hundred and eight patients were randomised. Patient characteristics and baseline demographics were similar among the groups. The proportions of patients achieving a clinical response were 25.1%, 27.6% and 27.2% for placebo, once daily and twice daily respectively; treatment differences were not significant (2.5%; 95% confidence interval, CI -6.1% to 11.0%, P = 0.546 for once daily vs. placebo, and 2.1%; 95% CI -6.5% to 10.7%, P = 0.648 for twice daily vs. placebo). Adverse events were reported in 69.8%, 73.3% and 78.1% with serious adverse events in 8.9%, 5.9%, and 6.0% of patients in the placebo, once-daily and twice-daily groups, respectively.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We did not demonstrate efficacy of vercirnon as an induction therapy in patients with moderately-to-severely active Crohn's disease; its effect in maintenance therapy was not addressed.</AbstractText><CopyrightInformation>© 2015 John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feagan</LastName><ForeName>B G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>Robarts Clinical Trials Inc, Robarts Research Institute, Western University, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sandborn</LastName><ForeName>W J</ForeName><Initials>WJ</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D'Haens</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Academic Medical Centre, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>S D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allez</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hopital Saint-Louis, APHP, Université Paris Diderot, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fedorak</LastName><ForeName>R N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, University of Alberta, Edmonton, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seidler</LastName><ForeName>U</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vermeire</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawrance</LastName><ForeName>I C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>School of Medicine and Pharmacology, University of Western Australia, Harry Perkins Institute for Medical Research, Fiona Stanley Hospital, Murdoch, WA, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for inflammatory Bowel Diseases, Saint John of God Hospital, Subiaco, WA, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maroney</LastName><ForeName>A C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jurgensen</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heath</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>GlaxoSmithKline, King of Prussia, PA, Research Triangle Park, NC, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aliment Pharmacol Ther</MedlineTA><NlmUniqueID>8707234</NlmUniqueID><ISSNLinking>0269-2813</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C119309">CC chemokine receptor 9</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C583420">CCX282-B</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D039841">Leukocyte L1 Antigen Complex</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054388">Receptors, CCR</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039841" MajorTopicYN="N">Leukocyte L1 Antigen Complex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054388" MajorTopicYN="N">Receptors, CCR</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>08</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>08</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26400458</ArticleId><ArticleId IdType="doi">10.1111/apt.13398</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Belgique</li><li>Canada</li><li>France</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Basse-Saxe</li><li>Californie</li><li>Hollande-Septentrionale</li><li>Pennsylvanie</li><li>Washington (État)</li><li>Île-de-France</li></region><settlement><li>Amsterdam</li><li>Hanovre</li><li>Paris</li><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="Canada"><noRegion><name sortKey="Feagan, B G" sort="Feagan, B G" uniqKey="Feagan B" first="B G" last="Feagan">B G Feagan</name></noRegion><name sortKey="Fedorak, R N" sort="Fedorak, R N" uniqKey="Fedorak R" first="R N" last="Fedorak">R N Fedorak</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Sandborn, W J" sort="Sandborn, W J" uniqKey="Sandborn W" first="W J" last="Sandborn">W J Sandborn</name></region><name sortKey="Chang, D J" sort="Chang, D J" uniqKey="Chang D" first="D J" last="Chang">D J Chang</name><name sortKey="Heath, A" sort="Heath, A" uniqKey="Heath A" first="A" last="Heath">A. Heath</name><name sortKey="Jurgensen, C H" sort="Jurgensen, C H" uniqKey="Jurgensen C" first="C H" last="Jurgensen">C H Jurgensen</name><name sortKey="Lee, S D" sort="Lee, S D" uniqKey="Lee S" first="S D" last="Lee">S D Lee</name><name sortKey="Maroney, A C" sort="Maroney, A C" uniqKey="Maroney A" first="A C" last="Maroney">A C Maroney</name></country><country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="D Haens, G" sort="D Haens, G" uniqKey="D Haens G" first="G" last="D'Haens">G. D'Haens</name></region></country><country name="France"><region name="Île-de-France"><name sortKey="Allez, M" sort="Allez, M" uniqKey="Allez M" first="M" last="Allez">M. Allez</name></region></country><country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Seidler, U" sort="Seidler, U" uniqKey="Seidler U" first="U" last="Seidler">U. Seidler</name></region></country><country name="Belgique"><noRegion><name sortKey="Vermeire, S" sort="Vermeire, S" uniqKey="Vermeire S" first="S" last="Vermeire">S. Vermeire</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Lawrance, I C" sort="Lawrance, I C" uniqKey="Lawrance I" first="I C" last="Lawrance">I C Lawrance</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002764 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002764 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:26400458
|texte= Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:26400458" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |